Reply to "New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin".
作者信息
Maronese Carlo Alberto, Di Zenzo Giovanni, Genovese Giovanni, Barei Francesca, Monestier Alice, Pira Anna, Moltrasio Chiara, Marzano Angelo Valerio
机构信息
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.
出版信息
Dermatol Ther. 2022 Jun;35(6):e15496. doi: 10.1111/dth.15496. Epub 2022 Apr 10.
Abstract
摘要
相似文献
1
Reply to "New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin".对“新型冠状病毒灭活疫苗接种后新发大疱性类天疱疮：新型冠状病毒疫苗与维格列汀的协同作用”的回复
Dermatol Ther. 2022 Jun;35(6):e15496. doi: 10.1111/dth.15496. Epub 2022 Apr 10.
2
New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin.新型冠状病毒灭活疫苗接种后新发大疱性类天疱疮：新型冠状病毒疫苗与维格列汀的协同作用
Dermatol Ther. 2022 Feb;35(2):e15241. doi: 10.1111/dth.15241. Epub 2021 Dec 8.
3
Vildagliptin-induced bullous pemphigoid.维格列汀诱发的大疱性类天疱疮
N Z Med J. 2021 Jun 25;134(1537):95-97.
4
The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.大疱性类天疱疮与二肽基肽酶 4 抑制剂的相关性：一项十年前瞻性观察研究。
BMC Endocr Disord. 2021 Feb 11;21(1):23. doi: 10.1186/s12902-021-00689-7.
5
Reply to 'The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?' by Damiani G et al.对达米亚尼等人所著《新冠病毒19疫苗首剂可能引发天疱疮和大疱性类天疱疮病情加重：那么第二剂是否因此禁忌接种？》的回复
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e433-e435. doi: 10.1111/jdv.17959. Epub 2022 Feb 4.
6
Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.维格列汀显著增加大疱性类天疱疮风险：一项芬兰全国性登记研究
J Invest Dermatol. 2018 Jul;138(7):1659-1661. doi: 10.1016/j.jid.2018.01.027. Epub 2018 Feb 7.
7
Bullous pemphigoid after inactivated COVID-19 vaccination: Case report.新型冠状病毒灭活疫苗接种后发生大疱性类天疱疮：病例报告
Dermatol Ther. 2022 Aug;35(8):e15595. doi: 10.1111/dth.15595. Epub 2022 Jun 7.
8
Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al.大疱性类天疱疮与新冠病毒疫苗接种：对Pauluzzi等人所著《一名年轻男性接种新冠病毒mRNA疫苗后发生大疱性类天疱疮：一例报告及文献简要综述》的管理与治疗回应
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e35-e36. doi: 10.1111/jdv.18503. Epub 2022 Aug 23.
9
Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.对Baffa等人的《新冠病毒疫苗接种后出现的严重大疱性类天疱疮，对利妥昔单抗耐药，用度普利尤单抗成功治疗》的回复
J Eur Acad Dermatol Venereol. 2023 May;37(5):e578-e580. doi: 10.1111/jdv.18893. Epub 2023 Jan 31.
10
Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.二肽基肽酶 4 抑制剂与 2 型糖尿病患者的大疱性类天疱疮相关：一系列 13 例病例。
Diabetes Metab Syndr. 2020 May-Jun;14(3):213-216. doi: 10.1016/j.dsx.2020.03.001. Epub 2020 Mar 4.
引用本文的文献
1
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.新型冠状病毒肺炎疫苗接种后的天疱疮和大疱性类天疱疮：一项系统评价
Viruses. 2024 Dec 9;16(12):1896. doi: 10.3390/v16121896.
2
COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.新冠疫苗：加速大疱性类天疱疮发病的潜在风险因素
Vaccines (Basel). 2024 Sep 5;12(9):1016. doi: 10.3390/vaccines12091016.
3
New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.新冠疫苗接种后自身免疫性大疱性皮肤病的新发与加重：一项系统评价
Vaccines (Basel). 2024 Apr 26;12(5):465. doi: 10.3390/vaccines12050465.
4
New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies.与新冠病毒疫苗相关的大疱性类天疱疮新发或复发：病例报告和病例系列研究的系统评价
Front Med (Lausanne). 2024 Apr 8;11:1293920. doi: 10.3389/fmed.2024.1293920. eCollection 2024.
5
Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study.回应：评论：与新冠疫苗相关的大疱性类天疱疮：一项意大利多中心研究。
Front Med (Lausanne). 2023 Mar 16;10:1160672. doi: 10.3389/fmed.2023.1160672. eCollection 2023.
6
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.新冠疫情期间的自身免疫性大疱性疾病：2022年利妥昔单抗与疫苗最新进展
Front Med (Lausanne). 2023 Jan 19;10:1112823. doi: 10.3389/fmed.2023.1112823. eCollection 2023.
7
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature.新冠疫苗接种后的皮肤反应：当前文献综述
Clin Cosmet Investig Dermatol. 2022 Nov 6;15:2369-2382. doi: 10.2147/CCID.S388245. eCollection 2022.
本文引用的文献
1
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.二肽基肽酶-4 抑制剂治疗的糖尿病患者并发大疱性类天疱疮：硬币的另一面。
J Transl Med. 2021 Dec 20;19(1):520. doi: 10.1186/s12967-021-03192-8.
2
New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin.新型冠状病毒灭活疫苗接种后新发大疱性类天疱疮：新型冠状病毒疫苗与维格列汀的协同作用
Dermatol Ther. 2022 Feb;35(2):e15241. doi: 10.1111/dth.15241. Epub 2021 Dec 8.
3
Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy.一名患有多种疾病且服用多种药物的84岁女性，在接种第一剂mRNA-1273疫苗后开始出现双相性大疱性类天疱疮，并在接种第二剂后病情加重。
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e88-e90. doi: 10.1111/jdv.17722. Epub 2021 Oct 12.
4
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study.临床与皮肤 COVID-19 疫苗反应的病理相关性，包括 V-REPP：一项基于注册的研究。
J Am Acad Dermatol. 2022 Jan;86(1):113-121. doi: 10.1016/j.jaad.2021.09.002. Epub 2021 Sep 10.
5
Impact of Sitagliptin on Non-diabetic Covid-19 Patients.西他列汀对非糖尿病 COVID-19 患者的影响。
Curr Mol Pharmacol. 2022;15(4):683-692. doi: 10.2174/1874467214666210902115650.
6
Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study.SARS-CoV-2 刺突蛋白受体结合域是否能与 DPP4（CD26）受体有效相互作用？一项分子对接研究。
Int J Mol Sci. 2021 Jun 29;22(13):7001. doi: 10.3390/ijms22137001.
7
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.二肽基肽酶-4（DPP-4）抑制剂与 2019 年冠状病毒病（COVID-19）患者死亡率：系统评价、荟萃分析和荟萃回归。
Diabetes Metab Syndr. 2021 May-Jun;15(3):777-782. doi: 10.1016/j.dsx.2021.03.027. Epub 2021 Apr 1.
8
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.二肽基肽酶-4 抑制剂相关性大疱性类天疱疮。
Front Immunol. 2019 Jun 4;10:1238. doi: 10.3389/fimmu.2019.01238. eCollection 2019.
9
Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work.物理因素在大疱性类天疱疮发病机制中的作用：病例报告系列及已发表文献的综合综述
J Dermatol. 2016 Feb;43(2):134-40. doi: 10.1111/1346-8138.13031. Epub 2015 Jul 15.
Zotero 插件